Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL)

Pediatric Blood and Cancer

Volumn 47, Issue 3, 2006, Pages 299-304

  Kwok, Cecilia Sze ^a   Kham, Shirley Kow ^a   Ariffin, Hany ^b   Lin, Hai Peng ^c   Quah, Thuan Chong ^a   Yeoh, Allen Eng ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^c SUBANG JAYA MEDICAL CENTRE   (Malaysia)

Author keywords

ALL; Drug efficacy; L asparaginase; Leukemia; Minimal residual disease

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; DAUNORUBICIN; DEXAMETHASONE; VINCRISTINE;

ACCURACY; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CELL KILLING; CHILDHOOD LEUKEMIA; CLEARANCE; COMPARATIVE STUDY; DEATH; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ERWINIA; ESCHERICHIA COLI; HUMAN; INFECTION; LEUKEMIA CELL; LIVER TOXICITY; LYMPHOBLAST; MAJOR CLINICAL STUDY; MEASUREMENT; MINIMAL RESIDUAL DISEASE; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SIDE EFFECT; STROKE; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; ERWINIA; ESCHERICHIA COLI; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33746594853     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20684     Document Type: Article

References (28)

1. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia-current status and future perspectives. Lancet Oncol 2001;2:597-607.
2. Broome JD. Evidence that the L-asparaginase activity of guinea-pig serum is responsible for its antilymphoma effects. Nature 1961;191:1114-1115.
3. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. Blood 2000;95:3310-3322.
4. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report. Leukemia 2000;14:2257-2266.
5. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-2233.
6. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy XIIIB at St Jude Children's Research Hospital. Blood 2004;104:2690-2696.
7. Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970;25:253-278.
8. Albertsen BK, Schrøder J, Ingerslev J, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: Pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 2001;115:983-990.
9. Asselin BL, Kreissman S, Coppola DJ, et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999;21:6-12.
10. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-1786.
11. Pinheiro JPV, Boos J. The best way to use asparaginase in childhood acute lymphatic leukemia-still to be defined? Br J Haematol 2004;125:117-127.
12. Vassilios IA, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future. Clin Pharmacokinet 2005;44:367-393.
13. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparaginase levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544-1550.
14. Rizzari C, Zucchetti M, Conter V, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 2000;11:189-193.
15. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Blood 2000;96:2691-2696.
16. Van Dongen JJM, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 1998;352:1731-1738.
17. Cavé H, Bosch JW, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998;339:591-598.
18. Sugahara K, Tsuruda K, Yamada Y, et al. Clonal analysis of B-cell leukemias and lymphomas using the polymerase chain reaction for the third complementarity determining region of the IgH gene: A study of 75 cases from Nagasaki Japan. Leuk Lymphoma 1999;34:387-393.
19. Szczepański T, Willemse MJ, van Wering ER, et al. Precursor-B-ALL with DH-JH gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 2001;15:1415-1423.
20. Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Leukemia 1999;13:110-118.
21. Langerak AW, Szczepański T, van der Burg M, et al. Heteroduplex PCR analysis of rearranged T-cell receptor genes for clonality assessment in suspect T-cell proliferations. Leukemia 1997;11:2192-2199.
22. van der Velden VH, Willemse MJ, van der School CE, et al. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002;16:928-936.
23. Verhagen OJ, Willemse MJ, Breunis WB, et al. Application of germline IgH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000;14:1426-1435.
24. Pongers-Willemse MJ, Verhagen OJHM, Tibbe GJM, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998;12:2006-2014.
25. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002;99:2734-2739.
26. Eden OB, Shaw MP, Lilleyman JS, et al. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukemia. Med Pediatr Oncol 1990;18:497-502.
27. Medicines and Healthcare products Regulatory Agency. Drug alert: Erwinase (Crisantaspase (Asparaginase)) 10,000 units/vial PL 13663/0001 [online]. 3 Feb 2003. Available from: http://www.mca.gov.uk/ourwork/monitorsafequalmed/ defmedsrepcen/camr.pdf
28. Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003;17:1583-1588.